Teijin and Merz Expand XEOMIN® Indications in Japan
Event summary
- Japan’s MHLW approved XEOMIN® for cervical dystonia and blepharospasm, adding to its existing indications in Japan.
- The approval is based on Phase III trials conducted by Merz and Teijin, reinforcing their 2017 co-development agreement.
- XEOMIN® is now approved in 79 countries worldwide, with therapeutic/aesthetic indications.
- Teijin Pharma launched exclusive sales of XEOMIN® in Japan in December 2020.
The big picture
This approval strengthens Teijin and Merz’s strategic partnership in addressing unmet needs in neurological conditions. The expansion of XEOMIN®’s indications aligns with Teijin’s long-term vision of focusing on rare diseases and difficult-to-treat conditions. The collaboration underscores the growing trend of cross-border partnerships in the pharmaceutical industry to accelerate drug development and market access.
What we're watching
- Market Penetration
- How Teijin and Merz will leverage this approval to expand XEOMIN®’s market share in Japan’s neurological treatment space.
- Regulatory Strategy
- Whether the companies will seek additional indications or expand into other Asian markets.
- Commercial Execution
- The pace at which Teijin can integrate and commercialize XEOMIN®’s new indications in Japan.
Related topics